188 related articles for article (PubMed ID: 35599363)
1. Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
Kayes T; Crane H; Symonds A; Dumond J; Cottrell M; Di Girolamo J; Manandhar S; Lim TH; Gane E; Kashuba A; Levy MT
Aliment Pharmacol Ther; 2022 Aug; 56(3):510-518. PubMed ID: 35599363
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load.
Li B; Liu Z; Liu X; Liu D; Duan M; Gu Y; Liu Q; Ma Q; Wei Y; Wang Y
Hepatol Int; 2021 Oct; 15(5):1103-1108. PubMed ID: 34312798
[TBL] [Abstract][Full Text] [Related]
3. Distribution Evaluation of Tenofovir in the Breast Milk of Mothers With HBeAg-Positive Chronic HBV Infection After Treatment With Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate by a Sensitive UPLC-MS/MS Method.
Yang N; Zhou G; Cheng X; He J; Chen Y; Chen C; Li M; Ge J; Wang M; Zhang T; Ge W; Zhu H; Han G
Front Pharmacol; 2021; 12():734760. PubMed ID: 34483946
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network.
Bukkems VE; Necsoi C; Hidalgo Tenorio C; Garcia C; Alba Alejandre I; Weiss F; Lambert JS; van Hulzen A; Richel O; Te Brake LHM; van der Meulen E; Burger D; Konopnicki D; Colbers A
Clin Infect Dis; 2022 Sep; 75(4):623-629. PubMed ID: 34864950
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes.
Chen HL; Lee CN; Chang CH; Lai MW; Tsai MC; Mu SC; Liu CJ; Shih JC; Wen WH; Hu RT; Huang CP; Hu KC; Chen CP; Lee CL; Chien RN; Chang KC; Hsu HY; Lee CC; Ni YH; Chang MH
Liver Int; 2024 Jun; 44(6):1422-1434. PubMed ID: 38456620
[TBL] [Abstract][Full Text] [Related]
6. Low levels of tenofovir in breast milk support breastfeeding in HBV-infected mothers treated with tenofovir disoproxil fumarate.
Li S; Jin J; Jiang Y; Shi J; Jiang X; Lin N; Ma Z
Int J Antimicrob Agents; 2023 Mar; 61(3):106726. PubMed ID: 36646229
[TBL] [Abstract][Full Text] [Related]
7. Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.
Bukkems VE; Smolders EJ; Jourdain G; Burger DM; Colbers AP; Cressey TR;
J Clin Pharmacol; 2021 Mar; 61(3):388-393. PubMed ID: 32960984
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study.
Zeng QL; Yu ZJ; Ji F; Li GM; Zhang GF; Xu JH; Chen ZM; Cui GL; Li W; Zhang DW; Li J; Lv J; Li ZQ; Liang HX; Sun CY; Pan YJ; Liu YM; Wang FS
Clin Infect Dis; 2021 Nov; 73(9):e3324-e3332. PubMed ID: 33395488
[TBL] [Abstract][Full Text] [Related]
9. The Use of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide for Preventing Vertical Transmission of Hepatitis B.
Zhu L; Park J; Deng Y; Pan CQ
J Clin Gastroenterol; 2023 Feb; 57(2):127-138. PubMed ID: 36598804
[TBL] [Abstract][Full Text] [Related]
10. Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.
Mugwanya KK; Hendrix CW; Mugo NR; Marzinke M; Katabira ET; Ngure K; Semiyaga NB; John-Stewart G; Muwonge TR; Muthuri G; Stergachis A; Celum CL; Baeten JM
PLoS Med; 2016 Sep; 13(9):e1002132. PubMed ID: 27676257
[TBL] [Abstract][Full Text] [Related]
11. Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide.
Lalley-Chareczko L; Hiserodt E; Moorthy G; Zuppa A; Mounzer K; Koenig H
Front Pharmacol; 2020; 11():286. PubMed ID: 32265700
[No Abstract] [Full Text] [Related]
12. Comparison of the efficacy and safety of TAF, TDF, and LdT to prevent the transmission of hepatitis B in pregnant women: A retrospective study.
Pan S; Zhang Y; Zeng Y; Lin C
Immun Inflamm Dis; 2024 Feb; 12(2):e1204. PubMed ID: 38414328
[TBL] [Abstract][Full Text] [Related]
13. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Podany AT; Bares SH; Havens J; Dyavar SR; O'Neill J; Lee S; Fletcher CV; Swindells S; Scarsi KK
AIDS; 2018 Mar; 32(6):761-765. PubMed ID: 29334548
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study.
Zeng QL; Zhang HX; Zhang JY; Huang S; Li WZ; Li GM; Pan YJ; Feng YH; Li ZQ; Zhang GF; Xu JH; Lin WB; Xu GH; Liu N; Zhang GQ; Li GT; Li W; Zeng YL; Song N; Wang M; Zhang DW; Chen ZM; Cui GL; Li J; Lv J; Liu YM; Liang HX; Sun CY; Zhou YH; Yu ZJ; Wang FS
Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2826-2837.e9. PubMed ID: 34902570
[TBL] [Abstract][Full Text] [Related]
15. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Agarwal K; Brunetto M; Seto WK; Lim YS; Fung S; Marcellin P; Ahn SH; Izumi N; Chuang WL; Bae H; Sharma M; Janssen HLA; Pan CQ; Çelen MK; Furusyo N; Shalimar D; Yoon KT; Trinh H; Flaherty JF; Gaggar A; Lau AH; Cathcart AL; Lin L; Bhardwaj N; Suri V; Mani Subramanian G; Gane EJ; Buti M; Chan HLY; ;
J Hepatol; 2018 Apr; 68(4):672-681. PubMed ID: 29756595
[TBL] [Abstract][Full Text] [Related]
16. Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.
Pan CQ; Chang TT; Bae SH; Brunetto M; Seto WK; Coffin CS; Tan SK; Mo S; Flaherty JF; Gaggar A; Nguyen MH; Çelen MK; Thompson A; Gane EJ
PLoS One; 2021; 16(5):e0251552. PubMed ID: 33984038
[TBL] [Abstract][Full Text] [Related]
17. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
Ruane PJ; DeJesus E; Berger D; Markowitz M; Bredeek UF; Callebaut C; Zhong L; Ramanathan S; Rhee MS; Fordyce MW; Yale K
J Acquir Immune Defic Syndr; 2013 Aug; 63(4):449-55. PubMed ID: 23807155
[TBL] [Abstract][Full Text] [Related]
18. Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Imaz A; Niubó J; Cottrell ML; Perez E; Kashuba ADM; Tiraboschi JM; Morenilla S; Garcia B; Podzamczer D
Clin Infect Dis; 2019 Sep; 69(8):1403-1409. PubMed ID: 30561517
[TBL] [Abstract][Full Text] [Related]
19. Plasma and Breast Milk Pharmacokinetics of Tenofovir Disoproxil Fumarate in Nursing Mother with Chronic Hepatitis B-Infant Pairs.
Erturk US; Mete B; Ozaras R; Saltoglu N; Balkan II; Mert A; Kacmaz B; Saglam O; Guney B; Sayman OA; Tabak F
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0111021. PubMed ID: 34310204
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis.
Jeong J; Shin JW; Jung SW; Park EJ; Park NH
Clin Mol Hepatol; 2022 Apr; 28(2):254-264. PubMed ID: 34959261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
